

November 20, 2015



Emmaus Life Sciences to Present at Maxim Group's Sickle Cell Disease Investor Conference on November 20

TORRANCE, Calif., Nov. 20, 2015 /PRNewswire/ -- Emmaus Life Sciences, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases, announced that management will present at Maxim Group's Sickle Cell Disease Investor Conference, "From Science to the Commercial Opportunity: How the Treatment Paradigm in Sickle Cell Disease is Changing," on November 20, 2015 in New York City.

About Emmaus Life Sciences

Emmaus Life Sciences is engaged in the discovery, development and commercialization of innovative treatments and therapies for rare diseases. The Company's research on sickle cell disease was initiated by Dr. Niihara at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. Emmaus' SCD therapy has Orphan Drug designation in the U.S. and Europe and Fast Track designation from the FDA.

For more information, please visit www.emmauslifesciences.com.

Contacts:

Media:

Lori Teranishi for Emmaus Life Sciences, Inc.
510-290-6160
lteranishi@iq360inc.com

Investors:

Matt Sheldon for Emmaus Life Sciences, Inc.
310-279-5975
msheldon@pondel.com

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/emmaus-life-sciences-to-present-at-maxim-groups-sickle-cell-disease-investor-conference-on-november-20-300182583.html>

SOURCE Emmaus Life Sciences, Inc.